CLINICAL STUDY
Down-regulation of cardioprotective bradykinin type-2 receptors in the left ventricle of patients with end-stage heart failure
Antti Kuoppala, MD*,
Naotaka Shiota, MD, PhD*,
Jorma O. Kokkonen, MD, PhD* ,
Inka Liesmaa, MD*,
Karam Kostner, MD, PhD ,
Mikko Mäyränpää, MD*,
Petri T. Kovanen, MD, PhD* and
Ken A. Lindstedt, PhD*,*
* Wihuri Research Institute, Helsinki, Finland
Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland
Division of Cardiology, Allegemeines Krankenhaus, Vienna, Austria
Manuscript received September 20, 2001;
revised manuscript received March 25, 2002,
accepted April 5, 2002.
* Reprint requests and correspondence: Dr. Ken A. Lindstedt, Wihuri Research Institute, Kalliolinnantie 4, FIN-00140 Helsinki, Finland. ken.lindstedt{at}wri.fi
OBJECTIVES: We sought to study the expression of bradykinin type-2 receptors (BK-2Rs) in patients with heart failure (HF).
BACKGROUND: Recent work in experimental animals has suggested that bradykinin (BK) exerts cardioprotective effects through specific BK-2Rs. However, nothing is known about the regulation of BK-2R expression in the pathogenesis of human HF.
METHODS: Human heart tissue was obtained from excised hearts of patients undergoing cardiac transplantation (n = 13) and from normal hearts (n = 6) unsuitable for donation. The patients had HF due to idiopathic dilated cardiomyopathy (IDC) (n = 7) or coronary heart disease (CHD) (n = 6). Tissue samples from the left ventricles were analyzed by competitive reverse-transcriptase-polymerase chain reaction and Western blotting for the expression of BK-2R messenger ribonucleic acid (mRNA) and protein.
RESULTS: In both the IDC and CHD hearts, the level of BK-2R mRNA expression was found to be significantly lower (30% and 38% of control values, respectively) than that in normal hearts. Correspondingly, the BK-2R protein level was significantly reduced in both the IDC and CHD hearts (45% and 62% of control values, respectively) and apparently involved all myocardial cell types. The down-regulation of BK-2R expression in failing hearts did not correlate with decreased cellularity or with the expression pattern of other members of the G-proteincoupled receptor superfamily. However, BK-2R down-regulation in the failing hearts was associated with a decrease in endothelial nitric oxide synthase in both IDC (53% of control value) and CHD (43% of control value) hearts.
CONCLUSIONS: These results are the first to suggest that a loss of BK-2Rs is involved in the pathogenesis of human HF.
|
Abbreviations and Acronyms
| | ACE | | angiotensin-converting enzyme | | AT-1R | | angiotensin II type 1 receptor | | AT-2R | | angiotensin II type 2 receptor | | BK | | bradykinin | | BK-2R | | bradykinin type-2 receptor | | CHD | | coronary heart disease | | DNA | | deoxyribonucleic acid | | eNOS | | endothelial nitric oxide synthase | | GAPDH | | glyceraldehyde-3-phosphate dehydrogenase | | HCAEC | | human coronary artery endothelial cell | | HF | | heart failure | | IDC | | idiopathic dilated cardiomyopathy | | LVH | | left ventricular hypertrophy | | PCR | | polymerase chain reaction | | RNA | | ribonucleic acid | | RT-PCR | | reverse-transcriptase polymerase chain reaction |
|
This article has been cited by other articles:

|
 |

|
 |
 
S. Helske, M. Laine, M. Kupari, J. Lommi, H. Turto, L. Nurmi, I. Tikkanen, K. Werkkala, K. A. Lindstedt, and P. T. Kovanen
Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves
Eur. Heart J.,
August 1, 2007;
28(15):
1894 - 1903.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. B. Keller and L. Lemberg
Statin Therapy in Congestive Heart Failure
Am. J. Crit. Care.,
July 1, 2005;
14(4):
338 - 340.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Liesmaa, A. Kuoppala, N. Shiota, J. O. Kokkonen, K. Kostner, M. Mayranpaa, P. T. Kovanen, and K. A. Lindstedt
Increased expression of bradykinin type-1 receptors in endothelium of intramyocardial coronary vessels in human failing hearts
Am J Physiol Heart Circ Physiol,
May 1, 2005;
288(5):
H2317 - H2322.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw
International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences
Pharmacol. Rev.,
March 1, 2005;
57(1):
27 - 77.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|